Abstract
Abstract Lyme disease is the most prevalent vector-borne infection in the United States. Lyme disease is a complex infection, and diagnosis has been hampered by inaccurate and irreproducible tests. Several new tests have recently become available. These include tests for exposure to Borrelia burgdorferi , such as the Lyme Borreliacidal Antibody Test (Lyme BAT) for borreliacidal antibodies to B. burgdorferi , the Lyme C6 enzyme immunoassay (Lyme C6 EIA), the Lyme PepC 10, and the Lyme Immune Complex assay. The Lyme BAT is indicative of protection by borreliacidal antibodies arising from effective vaccination or previous infection. The Lyme C6 EIA detects active infection and is very promising for monitoring the effectiveness of treatment. The PepC 10 may be a valuable test for early Lyme disease. Tests for immune complexes of Borrelia antigens and antibodies (Lyme immune complexes) can be used when clinical suspicion of Lyme disease is high and other tests are not definitive.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
